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Abstract
Introduction: The diagnostic efficacy of biochemical and imaging modalities for investigating the causes of
Cushing’s syndrome are limited. We report a case demonstrating the limitations of these modalities, especially the
inability of functional imaging to help localize the site of ectopic adrenocorticotropic hormone secretion.
Case presentation: A 37-year-old Arabian woman presented with 12 months of progressive Cushing’s syndrome-
like symptoms. Biochemical evaluation confirmed adrenocorticotropic hormone -dependent Cushing’s syndrome.
However, the anatomical site of her excess adrenocorticotropic hormone secretion was not clearly delineated by
further investigations. Magnetic resonance imaging of our patient’s pituitary gland failed to demonstrate the
presence of an adenoma. Spiral computed tomography of her chest only revealed the presence of a non-specific 7
mm lesion in her left inferobasal lung segment. Functional imaging, including a positron emission tomography
scan using 18-fluorodeoxyglucose and gallium-68-DOTA-D-Phe1-Tyr3-octreotide, also failed to show increased
metabolic activity in the lung lesion or in her pituitary gland. Our patient was commenced on medical treatment
with ketoconazole and metyrapone to control the clinical features associated with her excess cortisol secretion.
Despite initial normalization of her urinary free cortisol excretion rate, levels began to rise eight months after
commencement of medical treatment. Repeated imaging of her pituitary gland, chest and pelvis again failed to
clearly localize a source of her excess adrenocorticotropic hormone secretion. The bronchial nodule was stable in
size on serial imaging and repeatedly reported as having a nonspecific appearance of a small granuloma or lymph
node. We re-explored the treatment options and endorsed our patient’s favored choice of resection of the
bronchial nodule, especially given that her symptoms of cortisol excess were difficult to control and refractory.
Subsequently, our patient had the bronchial nodule resected. The histological appearance of the lesion was
consistent with that of a carcinoid tumor and immunohistochemical analysis revealed that the tumor stained
strongly positive for adrenocorticotropic hormone. Furthermore, removal of the lung lesion resulted in a
normalization of our patient’s 24-hour urinary free cortisol excretion rate and resolution of her symptoms and signs
of hypercortisolemia.
Conclusion: This case report demonstrates the complexities and challenges in diagnosing the causes of
adrenocorticotropic hormone -dependent Cushing’s syndrome. Functional imaging may not always localize the site
of ectopic adrenocorticotropic hormone secretion.
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The diagnostic efficacy of biochemical and imaging
modalities for localizing the anatomical site of ectopic
adrenocorticotropic hormone (ACTH) secretion are lim-
ited. Somatostatin receptor scintigraphy (SRS), using the
ligand 111-indium-pentetreotide, has traditionally been
the functional imaging technique used, but it’su s e f u l -
ness has been questioned [1]. Recently, positron emis-
sion tomography (PET) scanning using gallium-68-
DOTA-D-Phe1-Tyr3-octreotide (DOTATOC) has been
reported to be a superior modality for detecting neu-
roendocrine tumors [2]. However, here we describe a
case where this functional imaging technique failed to
localize the site of ectopic ACTH secretion.
Case presentation
A 37-year-old Arabian woman was referred to our endo-
crinology clinic with 12 months of progressive weight
gain of 30 kg, hirsutism, acne, alopecia, lethargy, ame-
norrhea and marked anxiety. An examination revealed
features of Cushing’s syndrome with rounded face, buf-
falo hump, abdominal striae and proximal muscle weak-
ness. Investigations confirmed excess cortisol
production. Her 24-hour urinary free cortisol excretion
was 1870 nmol/day (normal range 40-450 nmol/day),
her midnight salivary cortisol level was 121 nmol/L
(normal range < 9 nmol/L) and after a 1 mg overnight
dexamethasone suppression test her serum cortisol level
was 597 nmol/L (expected value < 50 nmol/L). Her
serum ACTH level was elevated at 55.8 and 55.1 ng/L
on two separate occasions (normal range 7-63.2 ng/L),
consistent with a diagnosis of ACTH-dependent Cush-
ing’s syndrome. Magnetic resonance imaging (MRI) of
her pituitary gland did not reveal the presence of an
adenoma.
L o c a l i z i n gt h es o u r c eo fe x c e s sA C T Hs e c r e t i o nw a s
challenging. Inferior petrosal sinus (IPS) sampling was
difficult due to a left petrosal sinus anatomical variation.
However, it demonstrated a central to peripheral ACTH
gradient of less than three, consistent with ectopic
ACTH secretion. This diagnosis was supported by fail-
ure of cortisol suppression (472 nmol/L) after an 8 mg
overnight dexamethasone suppression test. Computed
tomography (CT) of her chest, abdomen and pelvis only
revealed a well circumscribed 7 mm left inferior basal
lung segment lesion. This was reported to most likely
represent a benign granuloma or a small lymph node
(Figure 1).
Due to the wide range in sensitivity and specificity of
t h eh i g hd o s ed e x a m e t h a s o n esuppression test (59-92%
and 67-100%, respectively) and the inability to success-
fully catheterize her left IPS, further dynamic biochem-
ical tests were performed [3]. A five-hour intravenous
dexamethasone test suppressed her serum cortisol level
at five hours to less than 70% of basal values and a per-
ipheral corticotrophin-releasing hormone (CRH) test
showed a 58% increase in ACTH levels from baseline.
Contrary to preceding results, these findings could be
interpreted to suggest the presence of a pituitary source
for her excess ACTH secretion. However, PET scanning
using 18-fluorodeoxyglucose (FDG) and gallium-68-
DOTATOC failed to show increased metabolic activity
in the lung lesion or in her pituitary gland.
Serial CT scanning of her chest, abdomen and pelvis
over 18 months failed to definitively localize a source of
ectopic ACTH production. The well circumscribed 7
mm left inferior basal lung segment lesion was reported
as stable in size over this time. A repeat MRI of her
pituitary gland once again did not reveal the presence of
an adenoma.
Given the failure of biochemical or imaging techni-
ques to localize the site of excess ACTH secretion, med-
ical therapy was initiated with ketoconazole. However,
combination treatment with metyrapone was required
after eight months due to rising 24-hour urinary free
cortisol levels and progressive symptoms of weight gain,
lethargy, depression and anxiety. Despite combination
medical therapy there was still a progressive rise in 24-
hour urinary free cortisol leve l s( F i g u r e2 ) .A sar e s u l t ,
our patient again developed florid symptoms of weak-
ness, depression and anxiety which limited her daily
activities and interpersonal relationships.
Given the failure of medical therapy to control her
symptoms, other potential treatment options were dis-
cussed with our patient. These included progressing to
bilateral adrenalectomy or resection of the lung lesion,
w h i c hw a st h eo n l yp o s s i b l ea natomical site of ectopic
ACTH secretion located so far. Unfortunately, the lung
lesion was reported to be lying adjacent to the pericar-
dium which negated a minimally invasive surgical
Figure 1 Transverse image of a chest CT scan showing a small
7 mm inferobasal segment lesion (arrow) in the left lower lobe.
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strongly favored proceeding to resection of the lung
lesion even though this would require an open proce-
dure. Hence, an open thoracotomy to remove the lung
lesion was performed 18 months after her initial
presentation.
Histological examination of the resected nodule
showed a 9 mm well circumscribed tumor surrounding
a bronchus, with features consistent with a carcinoid
tumor. Immunohistochemical analysis revealed that the
tumor stained strongly positive for chromogranin,
synaptophysin and ACTH. Postoperative recovery was
uneventful and perioperative corticosteroid replacement
was progressively weaned. Clinically, her symptoms of
Cushing’s syndrome slowly abated. She achieved a nor-
mal 24-hour urinary free cortisol excretion off all treat-
ment four months after surgery. Our patient remains
well with no clinical or biochemical evidence of cortisol
excess seven months after her surgery.
Discussion
This case illustrates the difficulty in diagnosing a pitui-
tary or an ectopic source of ACTH-dependent Cushing’s
syndrome. A wide variability in the sensitivity and speci-
ficity of current biochemical dynamic tests has been
reported (Table 1). None of the current diagnostic tests
are able to differentiate between pituitary and ectopic
ACTH syndrome with 100% sensitivity and specificity.
Thus there is a need for a combination of tests to help
determine the cause of Cushing’s syndrome.
Furthermore, functional imaging may not always
assist in localizing an anatomical site of excess ACTH
secretion (Table 2). In some instances, ectopic ACTH-
secreting tumors can be detected by SRS using 111-
indium-pentetreotide, or as highlighted in a recent
case reported in this journal, with technetium-99 m-
labelled octreotide acetate [4]. However, the sensitivity
of SRS for detecting occult tumors that secrete ACTH
only ranges from 30 to 53% [1]. In contrast, some pre-
liminary reports have suggested that PET scanning
using gallium-68-DOTATOC yields a higher detection
rate of neuroendocrine tumors compared to SRS [2].
Despite this, the limitations of even this technique to
localize an ectopic source of ACTH secretion are high-
lighted by this case.
When all modalities fail to localize a source of ecto-
pic ACTH, the role of clinical judgment plays a signifi-
cant role. Ongoing monitoring of the patient,
combined with a relevant discussion of risks and bene-
fits of different therapeutic options led to a decision to
proceed to removal of the small bronchial nodule. This
nodule was subsequently confirmed to be an ACTH-
secreting carcinoid tumor. Embarking on this decision
despite there being no definitive preoperative confir-
m a t i o nt h a tt h en o d u l ew a st h es o u r c eo fh e re c t o p i c
ACTH production resulted i nac u r eo fo u rp a t i e n t ’s
Cushing’s syndrome.
Conclusion
We have shown the limitations of the currently available
diagnostic tools in differentiating pituitary or ectopic
sources of ACTH-dependent Cushing’ss y n d r o m e .
Furthermore, despite significant advances in radiological
and nuclear medicine imaging modalities, the localiza-
tion of the site of ectopic ACTH may still not be
possible.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any
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Figure 2 Pattern of 24-hour urinary free cortisol secretion
(normal range: 25-360 nmol/day) in response to various
treatment modalities. Note the horizontal axis is not to scale.
Table 1 Reported sensitivity and specificity of commonly
utilized dynamic biochemical diagnostic tests for
determining the site of excess ACTH secretion
Diagnostic Test Sensitivity Specificity
Overnight high dose dexamethasone
suppression test (8 mg) [3]
59-92% 67-100%
IV dexamethasone suppression test [5] 95-100% 40-90%
Ovine CRH stimulation test [5] 85-93% 85-90%
IPS sampling (central: peripheral gradient) [6] 81-85% 90-100%
Table 2 Reported sensitivity of current imaging
modalities for localizing the site of ectopic ACTH
secretion
Imaging Modalities Sensitivity Specificity
CT and MRI [7] 53 -74% n/a
111-indium pentetreotide SRS [1] 33-88% n/a
18-FDG PET scanning [8] 35-66% n/a
Gallium 68-DOTATOC PET scanning [2] 82% n/a
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Page 3 of 4accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this
journal.
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